Arase Yasuji, Suzuki Fumitaka, Akuta Norio, Sezaki Hitomi, Suzuki Yoshiyuki, Kawamura Yusuke, Kobayashi Masahiro, Hosaka Tetsuya, Yatsuji Hiromi, Hirakawa Miharu, Saito Satoshi, Ikeda Kenji, Kobayashi Mariko, Kumada Hiromitsu
Department of Hepatology, Toranomon Hospital, Tokyo.
Intern Med. 2009;48(5):253-8. doi: 10.2169/internalmedicine.48.1629. Epub 2009 Mar 2.
The aim of this study was to evaluate the efficacy of combination therapy of peginterferon and ribavirin in patients infected with hepatitis C virus (HCV) genotype 1b and low virus load.
Inclusion criteria were HCV-genotype 1b, serum HCV RNA level of < 100 KIU/mL at the initiation time of treatment. A total of 60 were enrolled in this retrospective cohort study. The treatment period of combination therapy was 39.8+/-16.1 weeks.
Of the 60 study patients, 47 had sustained virological response (SVR) by the intention to treat analysis. SVR occurred when serum HCV RNA was negative 8 weeks after the initiation of the treatment (p=0.004) and continuance of negative HCV RNA during treatment was > or = 30 week (p=0.016). In rapid virological response, all of seven patients with continuance of negative HCV RNA 20 to 29 weeks during treatment had SVR. In early virological response nine of 10 patients with continuance of negative HCV RNA of 30 to 39 week during treatment had SVR.
The duration of combination therapy for chronic hepatitis C should be determined based on the time of attainment of negative HCV RNA in patients with genotype 1b and low-virus load.
本研究旨在评估聚乙二醇干扰素和利巴韦林联合治疗对丙型肝炎病毒（HCV）1b型感染且病毒载量低的患者的疗效。
纳入标准为HCV 1b型，治疗开始时血清HCV RNA水平<100 KIU/mL。本回顾性队列研究共纳入60例患者。联合治疗的疗程为39.8±16.1周。
在60例研究患者中，47例经意向性分析获得持续病毒学应答（SVR）。治疗开始8周后血清HCV RNA呈阴性（p = 0.004）且治疗期间HCV RNA持续阴性>或=30周（p = 0.016）时出现SVR。在快速病毒学应答中，治疗期间HCV RNA持续阴性20至29周的7例患者均获得SVR。在早期病毒学应答中，治疗期间HCV RNA持续阴性30至39周的10例患者中有9例获得SVR。
对于1b型和低病毒载量的慢性丙型肝炎患者，联合治疗的疗程应根据HCV RNA转阴时间来确定。
